It’s time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. Citi’s new forecast now implies more than 50% upside from Friday’s close. The company is best known for its RNA-based therapeutics. Analyst David Lebowitz highlighted several key developments from the Ionis, including eplontersen — a medicine developed with AstraZeneca to treat amyloid transthyretin (ATTR) — as well as donidalorsen, a treatment for hereditary angioedema , which is currently expected to produce phase 3 test results in the first half of 2024. Phase 3 drug testing typically measures a given medication against an already proven treatment on the market. “Though HAE is a competitive market, Phase II data hints that it could have an attractive product profile and be a meaningful player,” Lebowitz said. “Notably, donidalorsen is wholly owned by Ionis. Given current valuation, we view the risk-reward on Ionis shares as being skewed positive.” Lebowitz also highlighted donidalorsen’s phase 2 test performance, which underpinned the stock upgrade. “Overall, donidalorsen appears to have a competitive profile, which should allow the therapy to carve out a meaningful market share, despite the competition,” he said. Ionis has climbed more than 6% this year. It gained more than 1% on Monday. IONS YTD mountain Ionis year to date — CNBC’s Michael Bloom contributed to this report.
FOLLOW US ON GOOGLE NEWS
Read original article here
Denial of responsibility! Chronicles Live is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email –
chronicleslive.com. The content will be deleted within 24 hours.
